Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine mepesuccinate in TKI-resistant/intolerant CML
NCT00462943Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2007
- Primary completion
- Aug 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of homoharringtonine in chronic myeloid leukemia (CML), sponsored by Teva Pharmaceutical Industries Ltd.. Started Mar 2007; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00462943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462943.